| 000 | 01984cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031902.0 | ||
| 008 | 171223s2017 ua h f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.31.Ph.D.2017.Sh.R | ||
| 100 | 0 | _aSherihan Mahmoud Saad | |
| 245 | 1 | 4 |
_aThe role of contrast enhanced spectral mammography in monitoring the response to neoadjuvant chemotherapy / _cSherihan Mahmoud Saad ; Supervised Rasha Kamal , Omnia Mokhtar , Mohamed Mohamed Gomaa |
| 246 | 1 | 5 | _aدور التصوير بالأشعة الرقمية للثدى بالصبغة فى مراقبة الاستجابة للعلاج الكيميائى المساعد |
| 260 |
_aCairo : _bSherihan Mahmoud Saad , _c2017 |
||
| 300 |
_a83 P. : _bfacsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Radio-diagnosis | ||
| 520 | _aBreast cancer is the most common cancer in women. Neoadjuvant chemotherapy (NAC); is the administration of chemotherapy to treat invasive breast cancer before surgery. The accurate assessment of residual tumor after NAC is a crucial prognostic factor for determining outcome and likely survival of the patient. The ability to distinguish between responsive and non-responsive patients is of critical importance for making treatment choices. Contrast enhanced spectral mammography (CESM) is an emerging modality currently under evaluation to determine its accuracy in the assessment of residual tumor after NAC | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aBreast cancer | |
| 653 | 4 | _aNeoadjuvant chemotherapy | |
| 653 | 4 | _aResponse monitoring | |
| 700 | 0 |
_aMohamed Mohamed Gomaa , _eSupervisor |
|
| 700 | 0 |
_aOmnia Mokhtar , _eSupervisor |
|
| 700 | 0 |
_aRasha Kamal , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c64176 _d64176 |
||